Cargando…

Istaroxime treatment ameliorates calcium dysregulation in a zebrafish model of phospholamban R14del cardiomyopathy

The heterozygous Phospholamban p.Arg14del mutation is found in patients with dilated or arrhythmogenic cardiomyopathy. This mutation triggers cardiac contractile dysfunction and arrhythmogenesis by affecting intracellular Ca(2+) dynamics. Little is known about the physiological processes preceding i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kamel, S. M., van Opbergen, C. J. M., Koopman, C. D., Verkerk, A. O., Boukens, B. J. D., de Jonge, B., Onderwater, Y. L., van Alebeek, E., Chocron, S., Polidoro Pontalti, C., Weuring, W. J., Vos, M. A., de Boer, T. P., van Veen, T. A. B., Bakkers, J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8660846/ https://www.ncbi.nlm.nih.gov/pubmed/34887420 http://dx.doi.org/10.1038/s41467-021-27461-8

Ejemplares similares

Rationale and design of the PHOspholamban RElated CArdiomyopathy intervention STudy (i-PHORECAST)
por: te Rijdt, W. P., et al.
Publicado: (2021)

Potential new mechanisms of pro-arrhythmia in arrhythmogenic cardiomyopathy: focus on calcium sensitive pathways
por: van Opbergen, C. J. M., et al.
Publicado: (2017)

Cellular Mechanisms Underlying the Low Cardiotoxicity of Istaroxime
por: Racioppi, María Florencia, et al.
Publicado: (2021)

Prevalence and cardiac phenotype of patients with a phospholamban mutation
por: Hof, I. E., et al.
Publicado: (2018)

Optogenetic sensors in the zebrafish heart: a novel in vivo electrophysiological tool to study cardiac arrhythmogenesis
por: van Opbergen, Chantal J.M., et al.
Publicado: (2018)

Efficacy of the New Inotropic Agent Istaroxime in Acute Heart Failure
por: Forzano, Imma, et al.
Publicado: (2022)

Istaroxime: A rising star in acute heart failure
por: Aditya, Suruchi, et al.
Publicado: (2012)

The phospholamban p.(Arg14del) pathogenic variant leads to cardiomyopathy with heart failure and is unreponsive to standard heart failure therapy
por: Eijgenraam, Tim R., et al.
Publicado: (2020)

Recurrent and founder mutations in the Netherlands—Phospholamban p.Arg14del mutation causes arrhythmogenic cardiomyopathy
por: van der Zwaag, P. A., et al.
Publicado: (2013)

Author Correction: The phospholamban p.(Arg14del) pathogenic variant leads to cardiomyopathy with heart failure and is unresponsive to standard heart failure therapy
por: Eijgenraam, Tim R., et al.
Publicado: (2020)

The phospholamban (PLN) p.Arg14del risk model; Longitudinal validation and reevaluation of predictors regarding sudden cardiac death (SCD)
por: Van Der Heide, M Y C, et al.
Publicado: (2023)

Optimal echocardiographic assessment of myocardial dysfunction for arrhythmic risk stratification in phospholamban mutation carriers( )
por: Taha, Karim, et al.
Publicado: (2021)

Identification and Functional Characterization of Cardiac Pacemaker Cells in Zebrafish
por: Tessadori, Federico, et al.
Publicado: (2012)

A randomized controlled trial of eplerenone in asymptomatic phospholamban p.Arg14del carriers
por: de Brouwer, Remco, et al.
Publicado: (2023)

Phospholamban cardiomyopathy: a Canadian perspective on a unique population
por: Cheung, C. C., et al.
Publicado: (2019)

A Heterozygous Mutation in Cardiac Troponin T Promotes Ca(2+) Dysregulation and Adult Cardiomyopathy in Zebrafish
por: Kamel, Sarah M., et al.
Publicado: (2021)

Mitochondrial Dysfunction as Substrate for Arrhythmogenic Cardiomyopathy: A Search for New Disease Mechanisms
por: van Opbergen, Chantal J. M., et al.
Publicado: (2019)

High Resolution Systematic Digital Histological Quantification of Cardiac Fibrosis and Adipose Tissue in Phospholamban p.Arg14del Mutation Associated Cardiomyopathy
por: Gho, Johannes M. I. H., et al.
Publicado: (2014)

Phospholamban antisense oligonucleotides improve cardiac function in murine cardiomyopathy
por: Grote Beverborg, Niels, et al.
Publicado: (2021)

In silico Identification of Disrupted Myocardial Calcium Homeostasis as Proarrhythmic Trigger in Arrhythmogenic Cardiomyopathy
por: Lyon, Aurore, et al.
Publicado: (2021)

The phospholamban p.Arg14del founder mutation in Dutch patients with arrhythmogenic cardiomyopathy
por: van der Heijden, J. F., et al.
Publicado: (2013)

Prediction of ventricular arrhythmia in phospholamban p.Arg14del mutation carriers–reaching the frontiers of individual risk prediction
por: Verstraelen, Tom E, et al.
Publicado: (2021)

Discovering and Visualizing Disease-Specific Electrocardiogram Features Using Deep Learning: Proof-of-Concept in Phospholamban Gene Mutation Carriers
por: van de Leur, Rutger R., et al.
Publicado: (2021)

Phospholamban R14del disease: The past, the present and the future
por: Vafiadaki, Elizabeth, et al.
Publicado: (2023)

Negative Adrenergic Feedback Specific to Phospholamban
por: Hasenfuss, Gerd, et al.
Publicado: (2017)

Phospholamban overexpression in mice causes a centronuclear myopathy-like phenotype
por: Fajardo, Val A., et al.
Publicado: (2015)

Safety and Efficacy of Istaroxime in Patients With Acute Heart Failure: A Meta-Analysis of Randomized Controlled Trials
por: Khalid Khan, Saad, et al.
Publicado: (2023)

Structures of PKA–phospholamban complexes reveal a mechanism of familial dilated cardiomyopathy
por: Qin, Juan, et al.
Publicado: (2022)

Effective CRISPR/Cas9-based nucleotide editing in zebrafish to model human genetic cardiovascular disorders
por: Tessadori, Federico, et al.
Publicado: (2018)

Istaroxime, a potential anticancer drug in prostate cancer, exerts beneficial functional effects in healthy and diseased human myocardium
por: Wallner, Markus, et al.
Publicado: (2017)

Impaired Right Ventricular Calcium Cycling Is an Early Risk Factor in R14del-Phospholamban Arrhythmias
por: Haghighi, Kobra, et al.
Publicado: (2021)

Blockade of the Adenosine 2A Receptor Mitigates the Cardiomyopathy Induced by Loss of Plakophilin-2 Expression
por: Cerrone, Marina, et al.
Publicado: (2018)

Antisense Therapy Attenuates Phospholamban p.(Arg14del) Cardiomyopathy in Mice and Reverses Protein Aggregation
por: Eijgenraam, Tim R., et al.
Publicado: (2022)

Sarcolipin deletion exacerbates soleus muscle atrophy and weakness in phospholamban overexpressing mice
por: Fajardo, Val A., et al.
Publicado: (2017)

A hallmark of phospholamban functional divergence is located in the N-terminal phosphorylation domain
por: Fernández-de Gortari, Eli, et al.
Publicado: (2020)

Blocking phospholamban with VHH intrabodies enhances contractility and relaxation in heart failure
por: De Genst, Erwin, et al.
Publicado: (2022)

Review: Precision Medicine Approaches for Genetic Cardiomyopathy: Targeting Phospholamban R14del
por: Deiman, Frederik E., et al.
Publicado: (2022)

Protein Aggregation Is an Early Manifestation of Phospholamban p.(Arg14del)–Related Cardiomyopathy: Development of PLN-R14del–Related Cardiomyopathy
por: Eijgenraam, Tim R., et al.
Publicado: (2021)

AKAP6 and phospholamban colocalize and interact in HEK‐293T cells and primary murine cardiomyocytes
por: Hakem Zadeh, Farigol, et al.
Publicado: (2019)

Myofilament Alterations Associated with Human R14del-Phospholamban Cardiomyopathy
por: Kumar, Mohit, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_pi7a75dn9h99a0hlgggu7pfdbh